Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06346067
Title	A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Acronym	SEACRAFT-2
Recruitment	Recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Erasca, Inc.
Indications	acral lentiginous melanoma skin melanoma
Therapies	LXH 254 + Trametinib Trametinib Dacarbazine Temozolomide
Age Groups:	senior \| adult
Covered Countries	USA \| NLD \| GBR \| FRA \| ESP \| CZE \| CAN \| AUS